Zhongsheng Pharmaceutical announced that the holding subsidiary obtained top-line analysis data results for the Phase I clinical trial of RAY1225 injection, a class 1 innovative drug.
众生药业：控股子公司一类创新药RAY1225注射液I期临床试验获得顶线分析数据结果
Zhongsheng Pharmaceutical: Phase I clinical trial of RAY1225 injection, a holding subsidiary, obtained top-line analysis data results
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.